IV PGI2 vs. Inhaled PGI2 in chronic lung disease
|
|
- Christine Marsh
- 5 years ago
- Views:
Transcription
1 Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has received grant/research support from Actelion Pharmaceuticals US, Inc., Bayer AG, Eli Lilly, Gilead Sciences, Inc., Novartis AG, Pfizer and United Therapeutics Corporation Has served as a consultant for Actelion, GIlead and United Therapeutics. Why the inhalation route for PH? Directly penetrates to target Vasodilates well ventilated areas avoiding V/Q mismatch Minimize systemic side effects (e.g. systemic hypotension) Avoid intravenous/sq route complications Potential for use in critical care settings IV PGI2 vs. Inhaled PGI2 in chronic lung disease Why the inhalation route for PH? Directly penetrates to target Vasodilates well ventilated areas avoiding V/Q mismatch Minimize systemic side effects (e.g. systemic hypotension) Avoid intravenous/sq route complications Potential for use in critical care settings Pediatric PAH in the critical care setting: Potential Target Populations for Inhaled Therapy Neonatal PAH PPHN CDH (congenital diaphragmatic hernia) BPD Pediatric PAH CHD perioperative Pre cardiac transplant with elevated PVR Acute PAH crisis 1
2 Inhaled Agents for Pediatric PAH Oxygen Inhaled nitric oxide (FDA approved) Inhaled iloprost (limited pediatric data) Inhaled treprostinil (no published pediatric data) Inhaled Nitric Oxide (NO) FDA approved in 1999 for use in near-term neonates with hypoxic respiratory failure Used frequently off label for many other forms of acute pulmonary hypertension Acute de-compensation in IPAH/APAH Perioperative use Acute vasodilator testing during catheterization At present not practical for long-term use in outpatient setting Not all patients respond to NO NINOS: Neonatal Inhaled Nitric Oxide Study Group (1997) Multicenter RCT to determine whether ino would reduce mortality or need for ECMO in infants with hypoxic respiratory failure ino was found to be a safe treatment which improved oxygenation and decreased the need for ECMO support. ino did not change the mortality rate 3% of infants had no significant response to ino at 2 ppm The Neonatal Inhaled NO Study Group, NEJM 1997 Response to ino: NINOS Response to ino Columbia NICU Diagnosis Patients (N=37) Percent of Total Median Treatment Time (Days) (Range) Average Treatment Time (Days) (SD) Percent Treatment Failures Non- Responders PPHN % 4 (.2-84) 6.1 (+/- 9.5) 32% CDH 57 15% 7 (.4-12) 12.2 (+/- 19.2) 6% Cardiac % 5 (.2-29) 5.5 (+/- 4.4) N/A NINOS, NEJM 1997 Subgroup of CDH patients (n=53); no difference in survival and increased need for ECMO Prematurity 49 14% 4 (1-12) 17.7 (+/- 26.4) N/A Rosenzweig, EB, Unpublished data 2
3 Rationale for Study of other PAH agents in Critical Care Setting Oxygen and Nitric Oxide don t always work What about Treatment of Long-Term PAH in Children? Alternative Inhaled Agents Treatment Rationale ino not readily available for chronic use at present until delivery modes are more portable Inhaled are less invasive than IV/SQ prostanoids Avoid SQ/IV complications Which patients to consider? Suboptimal response to oral therapy (FC III) Previous complications with SQ/IV prostanoids Inhaled Agents for Pediatric PAH Oxygen Inhaled nitric oxide Inhaled iloprost (limited pediatric data) Inhaled treprostinil Inhaled : Background FDA approved for adults with FC Class III and IV group 1 PAH in 24; 25 added indication as addon for symptomatic patients despite oral therapy Longer-acting prostacyclin analogue (2- to 3-min half-life) Still requires frequent inhalations (6 to 9x/d) ucg/inh 6-9 times per day Aerosolized delivery system Optimal delivery: 2.5-5um droplet size Time course of the effects of aerosolized iloprost on pulmonary vascular resistance (PVR) 4 devices EMEA app, 2 FDA app Hoeper, M. M. et al. JACC 2;35: in Pediatrics: Background Inhaled has been used worldwide in many adults with Group I PAH Outpatient data for pediatric patients are limited due to: Lack of pediatric data Difficulty in administering the medication in children < 7 years old via i-neb Frequency of inhalations; impact on quality of life Critical care setting data in children are also limited to case reports 3
4 AIR Study: Design AIR Study: Primary Endpoint AIR: Study Dosing Objective: Randomized, double-blind, placebocontrolled study (37 European centers in 11 countries) to assess efficacy of iloprost Duration: 12 weeks vs. Placebo monotherapy Patients: 23 patients with NYHA Class III or IV IPAH (5%) Chronic thromboembolic PH (28%) Associated with CTD (17%) Anorexigen use (4.5%) Olschewski H. N Engl J Med. 22;347: >1% Increase in 6 Minute Walk Combined Endpoint of Clinical Improvement Improvement in NYHA Functional Class (> 1 Class) Distance + + No Clinical Deterioration or Death Olschewski H. et al.,n Engl J Med or 5 mcg per treatment dose 6 to 9 doses/day while awake 9% of patients did not use during sleeping hours Median inhaled dose, 3 mcg/day Mean inhalations/day = 7.3 Olschewski H. N Engl J Med. 22. Percent responders 1 96 (n=68) 87 Placebo (n=78) AIR: Patient Improvement Approximately 5:1 Improvement vs. Placebo (Composite Primary Endpoint) No death or deterioration MWD 1% increase 3 min after inhalation 25 8 NYHA Class improvement p= Composite clinical endpoint Olschewski H. N Engl J Med Actelion Pharmaceuticals US, Inc. All rights reserved. Inhaled : Change From Baseline in 6MWD (AIR Trial) Mean change from baseline (m) Placebo (n=12) (n=11) Week 4 Placebo corrected change at 12 weeks: 36 meters Walks performed at dose peak Week 8 Week 12 p=.4 n=23 Olschewski H et al., N Engl J Med. 22 Change from baseline (%) AIR: Improved Hemodynamic Parameters Post Inhalation -23% PVR Cardiac Output P<.1 for the difference from baseline values. P<.5 for the difference from baseline values. +9% 15% -5% Placebo -9%.4% mpap Olschewski H. et al, 28 N Engl Actelion J Pharmaceuticals Med. 22;347: US, Inc. All rights reserved. 4
5 AIR-Trial () Summary Improvement in composite end point of clinical improvement (p<.1) Improvement in post inhalational walking distance (36 m, p=.4) Improvement in NYHA FC class (p<.5) Improvement in post inhalational hemodynamics (PVR, CO, PAPm) Improvement in quality of life (p<.5) Olschewski, et al. NEJM, 22 : Side Effects Vasodilation (flushing) Increased cough Headache Jaw pain Insomnia Nausea, vomiting Syncope STEP Study Design: added to Bosentan Objective Primary: Evaluate safety of adding iloprost to an endothelin receptor antagonist (ERA) Secondary: Efficacy endpoints (Clinical worsening, Functional class, Hemodynamics, 6MWT) Duration: or placebo added for 12 weeks to stable monotherapy with an ERA (mean ERA duration 18 months) Patients: 67 patients with PAH 55% IPAH; 45% Associated PAH 94% NYHA class III McLaughlin VV et al. Am J Respir Crit Care Med. 26 STEP Study Design: Prospective, randomized, double-bind, placebo-controlled, parallel-group ERA 125mg BID At least 16 weeks 2.5 mcg Placebo Baseline randomization 5mcg Placebo 1 Dose 12 weeks (n=34) (n=33) 3 months McLaughlin VV et al. Am J Respir Crit Care Med. 26. STEP: Primary Endpoint (Safety) Patients treated with an ERA tolerated the addition of inhaled iloprost Up to 5 mcg 6 to 9 times per day during waking hours Dosing Mean daily inhaled dose was 27 mcg Mean number of inhalations per day was 5.6 Safety trends were consistent with those observed in the larger AIR trial McLaughlin VV et al. Am J Respir Crit Care Med. 26 Inhaled Added to Bosentan (STEP) (n=67) Mean 6MWD Change from Baseline (m) Bosentan + (n=32) p=.51 Bosentan + Placebo (n=33) *log-rank test. McLaughlin VV et al. Am J Respir Crit Care Med. 26;174: Proportion Free of Clinical Worsening Placebo p=.2* Time (d) 5
6 Pediatric : Questions Are these data applicable to children? Is there a role for iloprost in the critical care setting? Is there a role for long-term iloprost in children? Safe? Effective? How would children manage the handheld device for long-term use? Delivery and dosing? Compliance? Pediatric PAH in the critical care setting: Target Populations/Early Experience Neonatal PAH PPHN CDH (congenital diaphragmatic hernia) BPD Pediatric PAH CHD perioperative Pre cardiac transplant with elevated PVR Acute PAH crisis in Neonatal PAH: Rationale Bronchopulmonary Dysplasia (BPD) widespread and Mortality rate in BPD patients with significant pulmonary hypertension is 5% and higher in some studies Chronic lung disease may cause significant VQ mismatch Other forms of neonatal PAH (e.g. PPHN, CDH) have significant failure rate with inhaled NO Delivery: Critical Care Setting PPHN: experience Neonatal case reports (n=4) Ehlen M, et al. treated 1 neonate with severe PPHN unresponsive to ino with iloprost Decreased RVSP by echo and improved oxygenation Conchiero GA, et al. described successful use of iloprost in 1 pt with PPHN De Luca D et al, described 2 cases of neonatal iloprost use (1- CDH, 1 PPHN) CDH pt improved PAP, but died of pneumothorax PPHN pt had significant improvement of PAP and was weaned from ventilator, but died of neurologic compromise Ehlen M, et al.,cardiol. Young, 23 Conchiero GA, et al., Ann Pediatr, 25 DeLuca D, et al., Paed Anesth, 27 Inhaled in Pediatric Patients (non-neonatal): CHD (n=28) Muller M et al, describe the use of iloprost during congenital heart surgery (ASD/VSD closure) following CPB (n=1) Rimensberger P, et al, compared ino and iloprost in children with CHD (n=15) Hallioglu O, et al, compare the acute hemodynamic effects of aerosolized and IV iloprost in PAH associated with CHD (n=12) Muller M et al., Anesthesiology, 23 Rimensberger P, et al., Circulation, 21 Hallioglu O, et al., Am J Cardiol, 23 6
7 Individual responses from all patients in Rp/Rs to ino and aerosolized iloprost (with exception of patient 1) vs. NO in peri-operative CHD Pediatric - CHD and Selectivity: Case report N=15 Rimensberger, P. C. et al. Circulation 21 Changes in Rp/Rs (*, solid line) and intracardiac shunt (Qp/Qs; {triangle up}, dotted line) in patient 1, showing inversion of shunt with ino and under iloprost aerosolization Rimensberger, P. C. et al. Circulation 21 Comparison of aerosolized and IV infusion of iloprost in 12 children (6 mos-16yrs) with PH secondary to CHD Cardiac Catheterization Baseline Hemodynamics administration: (25ng/kg/min x 1 minutes) IV administration > return to baseline> aerosolized administration Hallioglu O, et al., Am J Cardiol, 23 Pediatric : CHD and Selectivity (n=12) Case report (cont d) Inhaled iloprost Decrease in PAPm from to mmhg (p<.5) Rp/Rs decreased from to (p<.1) Increased the left to right shunt (p<.5) Intravenous iloprost Decrease in PAPm from to 4+19 mmhg However, no significant decrease in Rp/Rs ratio due to substantial fall in msap (71+12 vs mmhg) Did not have significant increase left to right shunt Hallioglu O, et al., Am J Cardiol, 23 : Pre- Cardiac transplant Pediatrics 17 year old patient with elevated PVR Received a combination of IV epoprostenol, dobutamine and aerosolized iloprost for 21 days while awaiting transplant Aggressive pre-treatment permitted heart vs. heart-lung transplant Underwent successful heart transplant Wittwer T, Ann Thorac Surg, 21 Short- and Long-Term Effects of Inhaled Therapy in Children With Pulmonary Arterial Hypertension Reported on the long-term experience in 22 pediatric patients Safety Dosing WHO FC, 6MW, Hemodynamics, vital stats Ivy, et al. JACC 28;51:
8 Study Population (n=22: patients receiving iloprost) Patients Gender - female 1 (45%) Age (years) 11.5 ( ) Weight (kg) 35.6 (15-73) Diagnosis IPAH 11 (5%) FPAH 1 (5%) PAH-CHD 1 (45%) Repaired (9) Unrepaired (2) Residual defect () Ivy, et al. JACC 28;51: Study Population: PH Medications at time of iloprost initiation (19/22) IV Prostanoid 9 Epoprostenol 3 Treprostinil 6 Sildenafil 16 Bosentan 11 CCB 3 Addition of PAH therapies after iloprost initiation: 7/22 Median time 2.4 months Ivy, et al. JACC 28;51: Dosing Six to nine inhalation treatments per day Minimum of 6 treatments per day (not PRN) Can be given prior to activity Dose tolerance challenge 2.5 mcg dose given If tolerated, 5. mcg dose given at next treatment Ivy, et al. JACC 28;51: Hemodynamics Effects of Acute in Pediatric PAH Following Chronic Therapy Hemodynamics Did Not Change : WHO Functional Class Baseline n=8 ino n=8 n=8 PAPm (mmhg) 66 ± ± 18* 57 ± 19* PVRI (units m2) 21 ± ± 17* 17 ± 15* Cardiac Index (L/min/m2) 2.9 ± ± ± 1.4 PCWPm (mmhg) 8 ± 2 8 ± 2 8 ± 3 RAPm (mmhg) 6 ± 4 6 ± 3 6 ± 3 Mean ± SD *P<.5 vs BL Reactive to ino and : 2/1 Ivy, et al. JACC 28;51: Baseline Before Chronic n=12 Baseline After Chronic n=12 PAPm (mmhg) 64 ± ± 13 PVRI (units m2) 22 ± ± 7 Cardiac Index (L/min/m2) 3.4 ± ± 1.4 PCWPm (mmhg) 9 ± 3 7 ± 2 RAPm (mmhg) 8 ± 3 6 ± 2 Mean ± SD Mean F/U: 1 ± 6 months 3/9 Off IV Prostanoid Ivy, et al. JACC 28;51: Patient Number Baseline n = 21/23 at 6months on therapy Improved 7 / Worsened 3 p =.5 6 Months WHO 4 WHO 3 WHO 2 Ivy, et al. JACC 28;51:
9 Pediatric : 6MW test change Six MinuteWalk Distance (m) ± 172 Baseline 6 Months 438 ± 17 Ivy, et al. JACC 28;51: Acute : FEF (Forced Expiratory Flow) FEF (% Predicted) of 14 showed a decrease in the FEF of more than 15 % (range %) p-value =.38 8 ± ± 28* Pre Post Ivy, et al. JACC 28;51: Future Direction of Inhaled in Pediatric PAH: Goals Identify appropriate target populations Protocol design to determine proper delivery and dosing, and to assess safety and efficacy Apply to long-term treatment of pediatric PAH patients Inhaled Agents for Pediatric PAH Oxygen Inhaled nitric oxide Inhaled iloprost Inhaled treprostinil Inhaled Treprostinil:?Pediatric PAH Inhaled Treprostinil FDA approved in 29 to increase walk distance in PH Group 1 patients with NYHA FC III symptoms Treprostinil is a longer acting prostanoid available in IV and SQ formulations requiring QID dosing No published data in children (ATS 211: abstract) OptiNeb : Ultrasonic Nebulizer Battery-operated (rechargeable) Single-breath technology Each treatment completed in about 1 minute May be easier for children to administer 9
10 Hemodynamics of Inhaled Treprostinil vs. Inhaled (n=44) Data from 44 patients who inhaled both drugs in randomized order, shown as percent of baseline values (mean ± 95% confidence interval). Voswinckel, R. et al. J Am Coll Cardiol 26 TRIUMPH-I: Study Design Randomize N=235 Key inclusion criteria NYHA class III or IV 6MWD of 2 to 45 m Bosentan or sildenafil for 3 months Therapy period Inhaled treprostinil (n=115) Inhaled treprostinil and placebo were initiated at 3 breaths q.i.d. and up-titrated up to 9 breaths (54 µg) q.i.d. as tolerated Placebo (n=12) 6 12 Weeks McLaughlin VV et al. J Am Coll Cardiol. 21 TRIUMPH-I Study: Inhaled Treprostinil Dosing Administered via treprostinil Inhalation System Inhaled treprostinil initiated at 3 breaths (18 µg) q.i.d. Dose titration up to a target of 9 breaths (54 µg) q.i.d. Mean time to achieve target breaths was 3 weeks TRIUMPH-I study q.i.d., 4 times daily. Number of breaths per treatment session Starting dose Target dose McLaughlin VV et al. J Am Coll Cardiol. 21 TRIUMPH-I: Baseline Demographics and Characteristics Characteristic Placebo (n=12) Inhaled treprostinil (n=115) Age, mean (range), y 52 (18-75) 55 (2-75) Female, n (%) 98 (82) 93 (81) PAH etiology, n (%) Idiopathic PAH CVD Other 67 (56) 37 (31) 16 (13) 64 (56) 4 (35) 11 (1) NYHA class III:IV, n 118:2 112:3 Oral PAH therapy, n (%) Bosentan Sildenafil Exposure to oral therapy, mean ± SD, weeks Bosentan Sildenafil 88 (73) 32 (27) 9 ± ± (67) 38 (33) 98 ± ± 6 6MWD, mean ± SD, m 351 ± ± 63 CVD, collagen vascular disease; 6MWD, 6-minute walk distance; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; SD, standard deviation. McLaughlin VV et al. J Am Coll Cardiol. 21 Inhaled Treprostinil: Median Change in 6MWD (TRIUMPH) 6MWD median change from baseline (m) p=ns 6 p=.1 19 Day 1 Week 6 peak Hodges-Lehmann estimate of treatment effect. Peak: between 1-6 min after dose. Trough: 4 hr after dose. p=.4 2 Week 12 peak p<.7 14 Week 12 trough McLaughlin VV et al. J Am Coll Cardiol. 21 TRIUMPH-I Study Clinical Summary Inhaled treprostinil for 12 weeks added to oral monotherapy for PAH improved 6MWD 82% of patients remaining in the study assessed at 1 year remained clinically stable on inhaled treprostinil without the need for additional PAH therapy Inhaled treprostinil adverse event profile Most common AEs (inhaled treprostinil vs placebo) Cough (54% vs 29%) Headache (41% vs 23%) Cough and throat irritation were considered related to inhalation route of delivery. McLaughlin VV et al. J Am Coll Cardiol. 21 1
11 Inhaled Treprostinil: Future Potential in Pediatric PAH? Requires clinical safety and efficacy data in children Requires dosing data in children Device potentially more user friendly for children Longer acting with less doses per day; potential impact for school age child Case series: Abstract at ATS 211 (n=18) highlights the Columbia and Colorado Pediatric PH Centers early experience Another role of the Inhaled Therapies in Children: Possible transitions off IV/SQ prostanoids 9/22 patients were transitioned off of a parenteral prostanoid to iloprost. (Ivy DD et al., JACC, 28) 13 children were successfully transitioned from IV prostanoid therapy to inhaled/oral PH therapy. 1/13 was transitioned to iloprost/bosentan combination. (Melnick L. et al, AJC, 21) Dana Point 29 PAH Evidence-based Treatment Algorithm Oral anticoagulants (E/B) IPAH/HPAH Supportive therapy and general measures Avoid excessive physical exertion (E/A) Diuretics (E/A) Birth control (E/A) Oxygen* (E/A) Psychological and social support (E/C) Digoxin (E/C) Expert referral (E/A) Infection prevention (E/A) Supervised rehabilitation (E/B) Acute vasoreactivity test (A for IPAH) (E/C for APAH) ACUTE RESPONDER NON-RESPONDER WHO Class I-IV Strength of Recommendation WHO Class II WHO Class III WHO Class IV Amlodipine, diltiazem, nifedipine (B) Ambrisentan, Bosentan, Ambrisentan, Bosentan, Epoprostenol IV A Sildenafil Epoprostenol IV, inh, Sildenafil Sitaxsentan, Tadalafil Sitaxsentan, Tadalafil, inh B Sustained response Treprostinil SC (WHO I-II) C Beraprost Treprostinil SC IV, Treprostinil IV IV, Treprostinil IV E/B Initial combination therapy (see below) Ambrisentan, Bosentan, YES NO E/C Sildenafil, Sitaxsentan, Tadalafil Not approved Treprostinil inh+ Treprostinil inh+ Amlodipine, diltiazem, INADEQUATE CLINICAL RESPONSE nifedipine (B) Sequential combination therapy INADEQUATE CLINICAL RESPONSE Atrial septostomy (E/B) and/or + (B) Prostanoids + (B) lung transplant (E/A) PDE-5 I + (B) ERA Barst RJ et al. JACC. 29 Summary: Inhaled Therapies for PAH in children Inhaled therapies including oxygen and NO are used routinely in the critical care setting and to evaluate acute vasoreactivity in the catheterization lab The study of alternate agents such as iloprost and inhaled treprostinil may offer other options for pediatric patients in both the critical and out-patient setting Further study of these agents are necessary to provide the safety, efficacy, dosing and optimal delivery modes for children 11
12 2mcg/mL Drug Delivery Data Volume of solution emitted 1 mcg/ml (.5 ml chamber) 2 mcg/ml (.25 ml chamber).46 ml.25 ml Dose emitted 4.54 mcg 4.97 mcg Fine particle fraction (% < 4.7 µm) Simulated dose delivery time 95.4% 9.1% 1 min 3.8 min *Validation data based on particle sizing into an Andersen Cascade Impactor with a manually generated 28.3 L/min 15-second inhalation cycle breathing pattern (data on file, Actelion Pharmaceuticals) 12
Disclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationTreatment of Paediatric Pulmonary Hypertension
Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationSTARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125:
STARTS-1 and -2 A randomized, double-blind,16 week placebo controlled, dose ranging, parallel group study of oral monotherapy sildenafil in treatment naive children, aged 1-17 years, with pulmonary arterial
More informationIntravenous Therapies for Pulmonary Hypertensive Vascular Disease. Intravenous Treatment for PAH: Past, Present and Future 3/10/2012
Intravenous Therapies for Pulmonary Hypertensive Vascular Disease Robyn J Barst MD Professor Emeritus Columbia University New York, NY March 1 th 212 Presented By: Erika Berman Rosenzweig, MD Dr. Robyn
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationContreversies in the management of PH What is controversial in treatment?
Contreversies in the management of PH What is controversial in treatment? Service de Pneumologie et Réanimation National reference center for pulmonary hypertension Université Paris Sud Hôpital Antoine
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationObjectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease
Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine)
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationPulmonary Vasodilator Treatments in the ICU Setting
Pulmonary Vasodilator Treatments in the ICU Setting Lara Shekerdemian Circulation 1979 Ann Thorac Surg 27 Anesth Analg 211 1 Factors in the ICU Management of Pulmonary Hypertension After Cardiopulmonary
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationComparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry
nazzareno.galie@unibo.it Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry Nazzareno Galiè, MD, FESC, FRCP (Hon), DIMES 2 Comprehensive clinical classification
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationClass Update with New Drug Evaluation: Drugs for Pulmonary Arterial Hypertension
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationUSE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014
USE OF INHALED NITRIC OXIDE IN THE NICU East Bay Newborn Specialists Guideline Prepared by P Joe, G Dudell, A D Harlingue Revised 7/9/2014 ino for Late Preterm and Term Infants with Severe PPHN Background:
More informationPaediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of pulmonary arterial hypertension
5 December 2011 EMA/CHMP/213972/2010 Committee for Medicinal Products for Human use (CHMP) Paediatric addendum to CHMP guideline on the clinical investigations of medicinal products for the treatment of
More informationINSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)
INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) N. S. Hill; J. P. Feldman; S. Sahay; D. J. Levine; R. F. Roscigno;
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationEffects of Long-Term Bosentan in Children With Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 46, No. 4, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.01.066
More informationΠνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION. Αναστασία Ανθη
Πανελλήνια Σεμινάρια Ομάδων Εργασίας 2017 k Πνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό Ιατρείο Πνευμ. Υπέρτασης Π.Γ.Ν.
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationAdvanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension. Original Policy Date
MP 5.01.07 Advanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationUntreated idiopathic pulmonary arterial hypertension
Congenital Heart Disease Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension Delphine Yung, MD; Allison C. Widlitz, MS, PA; Erika Berman Rosenzweig, MD; Diane Kerstein, MD; Greg Maislin,
More informationShort- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 51, No. 2, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.09.031
More information*Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors James R Klinger,* Raymond
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationRaymond L. Benza, MD, a Mardi Gomberg-Maitland, MD, MSc, b Robert Naeije, MD, PhD, c Carl P. Arneson, MStat, d and Irene M.
http://www.jhltonline.org Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationMedical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines
CHEST Clinical Practice Guidelines Medical Therapy for Pulmonary Arterial Hypertension* Updated ACCP Evidence-Based Clinical Practice Guidelines David B. Badesch, MD, FCCP; Steven H. Abman, MD; Gerald
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationUpdates on Pulmonary Hypertension Treatment
Updates on Pulmonary Hypertension Treatment Dane Mellgren, PharmD PGY-1 Pharmacy Practice Resident Hennepin County Medical Center 04/27/18 Disclosure I have no disclosures to be made regarding the content
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPulmonary Hypertension - Current Perspectives. Dr. Dipesh Maskey Dept of Pulmonology and CCM PGIMER,CHD 29/01/2010
Pulmonary Hypertension - Current Perspectives Dr. Dipesh Maskey Dept of Pulmonology and CCM PGIMER,CHD 29/01/2010 Pulmonary Hypertension Characterized by Restricted flow through the pulmonary arterial
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationPulmonary Arterial Hypertension (PAH) Treatments
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationReview Report. Epoprostenol ACT 1.5 mg. Actelion Pharmaceuticals Japan Ltd. Date of Application March 04, 2016 Dosage Form/Strength
Review Report January 18, 2017 Pharmaceuticals and Medical Devices Agency The following are the results of the review of the following pharmaceutical product submitted for marketing approval conducted
More informationTadalafil for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004
More informationClinical History. CHD-PAH Case: Physical Exam. Clinical History. To Repair or not to Repair?
CHD-PAH Case: To Repair or not to Repair? Erika Berman Rosenzweig, MD Columbia University, College of Physicians and Surgeons Clinical History 18 year old female had been previously well, but new murmur
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.18 Revision Log See Important Reminder at the end of this policy for important
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationThe US REVEAL Registry
Pulmonary Hypertension: Lessons from Contemporary Registries The US REVEAL Registry ESC August 30, 2010 Dave Badesch, MD University of Colorado Disclosures Dr. Badesch has received grant/research support
More informationPulmonary Hypertension: Evolution and
Management of Pulmonary Hypertension: Evolution and Controversies VERMONT CARDIAC NETWORK SPRING CONFERENCE MAY 10, 2018 MARYELLEN ANTKOWIAK, MD, PULMONARY & CRITICAL CARE MEDICINE, UVMMC WHO classification
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationClinical Policy: Treprostinil (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date:
Clinical Policy: (Orenitram, Remodulin, Tyvaso) Reference Number: ERX.SPA.36 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other SELEXIPAG UPTRAVI 42922 TREPROSTINIL ORENITRAM ER 40827 If the caller wishes to initiate a request then a MRF must be completed. This drug requires a written request
More information5/30/2014. Pulmonary Hypertension PULMONARY HYPERTENSION. mean PAP > 25 mmhg at rest. Disclosure: none
Disclosure: Pulmonary Hypertension none James Ramsay MD Medical Director, CV ICU, Moffitt Hospital, UCSF PULMONARY HYPERTENSION mean PAP > 25 mmhg at rest Pulmonary Hypertension and Right Ventricular Dysfunction:
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2020-10 Program Prior Authorization/Medical Necessity PAH Agents Medication Adcirca (tadalafil), Adempas (riociguat), Letairis
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationPharmacologic Treatment of Pulmonary Hypertension
12 Articole preluate din publicaţii internaţionale Pharmacologic Treatment of Pulmonary Hypertension Nnenna L. Iheagwara, PharmD, BCPS 1 ; Tyan F. Thomas, PharmD, BCPS 2 1 Primary Care Clinical Pharmacy
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationIntravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Eur Respir J 2002; 20: 339 343 DOI: 10.1183/09031936.02.02462001 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2002 European Respiratory Journal ISSN 0903-1936 Intravenous iloprost for
More informationPulmonary Hypertension: We have come a Long Way
Pulmonary Hypertension: We have come a Long Way Shelley Shapiro M.D. Ph.D Pulmonary Hypertension Program 9001.01 1 2 Disclosures Grant Support Gilead, United Therapeutics, Actelion, GeNO, Medtonics, Bellerphon,
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 10/1/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationDisclosure Information:
Emerging Pharmacological Treatment Approaches/Novel Pathways: Strengths, Gaps, Unmet Needs Robyn J Barst Columbia University College of Physicians & Surgeons New York, NY March 12, 211 Scientific Advisory
More informationManaging Multiple Oral Medications
Managing Multiple Oral Medications Chris Archer-Chicko, MSN, CRNP PENN Presbyterian Medical Center Arlene Schiro,, CRNP Massachusetts General Hospital Mary Bartlett, CRNP Winthrop University Hospital PH
More informationWhat Surgeons Need to Know About. Pulmonary Arterial Hypertension
What Surgeons Need to Know About Pulmonary Arterial Hypertension David B. Badesch, MD Professor of Medicine University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch
More informationPharmacologic Treatment of Neonatal Pulmonary Hypertension
Pharmacologic Treatment of Neonatal Pulmonary Hypertension Steven H. Abman, MD Professor of Pediatrics Director, Pediatric Heart Lung Center University of Colorado School of Medicine and Children s Hospital
More informationAdvanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
MEDICAL POLICY 5.01.522 Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension BCBSA Ref. Policy: 5.01.09* Effective Date: Dec. 1, 2017 Last Revised: Nov. 21, 2017 Replaces:
More informationPediatric Pulmonary Hypertension: Inside Out
Pediatric Pulmonary Hypertension: Inside Out Asma Razavi, MD Assistant Professor Pediatric Critical Care Medicine Loma Linda University Children s Hopsital Disclosures I have no conflicts of interest to
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationLong-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
Eur Respir Rev 2009; 18: 114, 253 259 DOI: 10.1183/09059180.00003109 CopyrightßERSJ Ltd 2009 REVIEW Long-term outcome in pulmonary arterial hypertension: a plea for earlier parenteral prostacyclin therapy
More informationCurrent and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06
Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06 Pulmonary Hypertension A mean pressure of greater than 25 mm Hg at rest (normal ~14 mm Hg) or greater
More informationProstacyclin has potent vasodilatory,
Eur Respir Rev 29; 18: 111, 29 34 DOI: 1.1183/95918.11111 CopyrightßERSJ Ltd 29 Inhaled iloprost for the treatment of pulmonary hypertension H. Olschewski ABSTRACT: Prostacyclin and its analogues (prostanoids)
More information(CHEST 2004; 126:35S 62S)
Medical Therapy For Pulmonary Arterial Hypertension* ACCP Evidence-Based Clinical Practice Guidelines David B. Badesch, MD, FCCP; Steve H. Abman, MD; Gregory S. Ahearn, MD; Robyn J. Barst, MD; Douglas
More informationPulmonary Hypertension Associated with Congenital Heart Disease. Amiram Nir Hadassah, Jerusalem
Pulmonary Hypertension Associated with Congenital Heart Disease Amiram Nir Hadassah, Jerusalem Disclosure Honoraria - Actelion Research grants form Actelion The Nice Classification (2013) Blok et al. Expert
More information